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Lamotrigine is a new generation antiepileptic which blocks sodium channels and can cause significant toxicity in overdose. A
case of a three-year-old child who suffered a seizure and required endotracheal intubation after accidental lamotrigine ingestion is
presented. The lamotrigine concentration measured 23.2 mcg/mL which is the highest reported after accidental pediatric exposure.
A review of the literature regarding pediatric lamotrigine poisoning is also included.

1. Introduction
Lamotrigine was developed in 1994 and is prescribed for both
partial and generalized seizures as well as bipolar disorder.
The drug inhibits seizure activity primarily through voltagegated sodium channel blockade. It also acts presynaptically as
an inhibitor of glutamate and aspartate. In the postsynaptic
setting, it diminishes excitability by inhibiting sodium conductance and may also reduce high-voltage activated calcium
currents [1–3]. Unlike other anticonvulsants, lamotrigine has
little or no effect on serotonergic, dopaminergic, or adrenergic receptors [2, 4]. Reported adverse effects with therapeutic
use include nausea, vomiting, diplopia, dizziness, ataxia,
tremor, and urinary tract infections. Most effects are mild
to moderate in intensity and do not lead to discontinuation
[1, 2]. More serious adverse events are dermatologic, such
as Stevens-Johnson Syndrome, which appears to be more
common in children than adults [2].

2. Case Presentation
A three-year-old, 14.5 kg boy, without medical history and
prescribed no medications, presented to the emergency
department (ED) within an hour of ingesting between seven

and sixteen oral disintegrating 25 mg lamotrigine tablets and
one to six 0.5 mg clonazepam tablets from his brother’s pill
organizer.
Emergency Medical Services arrived at the home within
20 minutes of ingestion and found the patient minimally
responsive and arousable only to painful stimuli with poor
respiratory effort. Bag-valve-mask ventilation was provided.
An intraosseous (IO) line was established, and the patient was
transported to the ED.
In the ED, the child had a Glasgow Coma Scale of
3 and minimal independent respiratory effort. Vital signs
included heart rate of 100 beats per minute, pulse oximetry
100% (100% oxygen via bag-valve mask), temperature 35.7∘C
(96.2∘ F), and blood pressure 92/43 mmHg. The child then
developed a tonic-clonic seizure which was treated with 1
mg IO lorazepam. The patient was endotracheally intubated
for airway protection and admitted to the pediatric intensive care unit (PICU) for further monitoring and care. An
electrocardiogram (QRS interval of 86ms), complete blood
count, serum chemistries, serum acetaminophen, salicylate
and ethanol concentrations were all unremarkable.
Serum lamotrigine concentrations measured 23.2
mcg/mL and 18.5 mcg/mL approximately three and 24 hours
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Table 1: Case reports of pediatric seizures following lamotrigine ingestion.

Reference

Age, sex

Dose, formula

Presentation

3-year-old
male

Up to 27.6
mg/kg in ODT
tablets

Acute: 1 seizure <1 minute
in duration within 1 hour
with myoclonic activity,
dysconjugate gaze, coma

Grosso
(2016)

3.2-year-old
male

1600 mg total
(wt not given)
200 mg tablets

Acute: tonic-clonic status
epilepticus upon
presentation. After 30 min
postictal pattern

Moore
(2013)

1-year-old
female

Unknown
quantity

Close
(2010)

2-year-old
male

Up to 43 mg/kg
tablet

Present
case

Thundiyil 19-month-old
(2007)
male

Unknown
amount of a
chewable tablet

Willis
(2007)

12-day-old
male

Not available

Lofton
(2004)

3-year-old
female

Not available

Briassoulis
(1998)

2-year-old
male

62 mg/kg tablet

Acute: initially agitated and
crying with intermittent
myoclonus of her
extremities
Acute: 2 seizures of
5-second duration within 3
hours with ataxia,
drowsiness, nystagmus,
hyperreflexia vomiting
Acute: 2 seizures of
<10-second duration in 1
hour with irritability,
vomiting, sinus tachycardia
Acute: repeated poisoning
(including in the hospital);
2 seizures (9 days apart),
with arm movements,
irritability, poor
interaction, poor feeding
Acute: multiple seizures
with vomiting
Acute: 2 seizures (15- and
5-minute duration) within
90 minutes with muscle
weakness and
incoordination, ataxia,
tremor, hypertonia

Drug
concentration
23.2 mcg/mL
(3-4-hour level) &
18.5 mcg/mL
(24-hour level)

Management

Outcome

Lorazepam,
intubation

Discharged well
after 72 hours

28.4 mg/L after 10
hours of fluids

Rectal diazepam x
2, IVP
midazolam, then
cont infusion

Discharged at
approx 72 hrs.
Hyperphagia still
present at
discharge

18 mg/L at 8 h and
11.8 mg/L at 19 h

Lorazepam

Discharged well
after 19 hours

Not available

Diazepam

Discharged well
after 12 hours

20.3 mg/L (1-hour
level)

Activated charcoal

Discharged well
after 24 hours

35 mg/L (2 days
after the second
seizure)

Lorazepam,
phenytoin,
paraldehyde

19-day admission
with seizures at
days 4 and 13,
discharged well to
child protection

Not available

Not available

Not available

3.8 mg/L (2-hour
level)

Midazolam, gastric
lavage, activated
charcoal

Discharged well
after 48 hours

Modified from the following: Close BR, Banks CJ: Seizures secondary to lamotrigine toxicity in a two-year-old. Ann Pharmacother 2010;44:1112-5.

after ingestion, respectively. Serum liquid chromatographymass spectrometry detected the following: acetaminophen,
lamotrigine, 7-aminoclonazepam, midazolam, alphahydroxymidazolam, and lorazepam. This result is consistent
with both ingestion of lamotrigine and clonazepam, as well
as iatrogenic administration of lorazepam, midazolam, and
acetaminophen.
While in the PICU, the child demonstrated mild hyperkinesia and periods of agitation. He was extubated on
hospital day (HD) one, and these symptoms resolved over the
subsequent 36 hours. Ultimately, the patient was discharged
in normal condition on HD five.

3. Discussion
Lamotrigine poisoning in children is very rare. Seven
identified cases of patients describe seizures, as well as

hyperkinesia and ataxia following ingestion [3, 5–10]. These
case reports of acute lamotrigine poisoning in pediatric
patients were identified through literature review (Table 1).
Case reports of lamotrigine intoxication in children were
identified by searching PubMed using the following search
terms: lamotrigine, lamictal, overdose, poisoning, pediatric,
seizure, and adverse reactions. Case reports describing adult
patients with adverse reactions as well as adverse reactions
resulting from therapeutic dosing or chronic ingestion were
excluded. Three cases of pediatric lamotrigine poisoning
which included serum concentrations were identified. The
highest documented serum concentration was measured in
a 12-day-old boy who was being repeatedly poisoned while in
the hospital and not after a single, accidental ingestion as in
the case described in this report [5].
Lamotrigine is rapidly absorbed in the stomach with
a bioavailability of approximately 98%. The drug is 50%
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plasma protein-bound, undergoes hepatic metabolism via
glucuronidation, and is mainly eliminated by the kidneys
with an elimination half-life of approximately 29 hours [1,
11]. Oral disintegrating tablets and regular immediate release
oral tablets are bioequivalent [11]. Typically, the maximum
lamotrigine dosage for maintenance in the pediatric age
group is a maximum of one to five mg/kg/day divided into
one or two doses. The largest potential dose consumed in our
case was five times the maximum maintenance dosage for his
age group [7].
Lamotrigine poisoning can cause seizures, behavioral
disturbances, and cardiotoxicity. Seizures generally occur
between 20 minutes and three hours after ingestion and
have been described as myoclonic, tonic- clonic, and status
epilepticus (Table 1). Hyperkinetic arm motion, dysconjugate
gaze, and ataxic gait were evident on physical examination
in this case. Severe ataxia and dysmetria have been reported
and attributed to inhibition of GABA release [12]. Oculogyric
crisis may occur from alteration of dopaminergic tone [12].
Neurologic effects generally resolve over 12 to 48 hours.
While there have been no reported cases of cardiotoxicity
in the pediatric population, this is a known risk of lamotrigine intoxication causing ventricular dysrhythmias in
adults.
Treatment of lamotrigine poisoning comprises airway
support and the use of titrated benzodiazepines, barbiturates, or propofol to ameliorate seizure and motor activity
[13]. Administration of intravenous sodium bicarbonate is
indicated for prolonged QRS interval or ventricular dysrhythmias. Intralipid emulsion administration with clinical
improvement was reported in a case of a patient suffering
from combined lamotrigine and bupropion toxicity [14].
Measurement of serum lamotrigine concentrations may be
used to confirm exposure but may not be readily available;
therefore, empiric treatment as outlined above is recommended.
Pediatric lamotrigine poisoning can cause severe toxicity,
including abnormal motor activity, seizures, and possible
cardiac dysrhythmias. The mainstay of treatment is empiric
and supportive with attention to the airway and control of
seizures.
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